

## Evrysdi<sup>®</sup> (risdiplam) – New formulation approval

- On February 11, 2025, <u>Roche announced</u> the FDA approval of <u>Evrysdi (risdiplam)</u> 5 mg tablet, for the **treatment of spinal muscular atrophy (SMA) in pediatric and adult patients**.
- **Evrysdi tablet is a new formulation of risdiplam**. Evrysdi is also approved as a 60 mg powder for constitution to provide a 0.75 mg/mL oral solution.
- The approval of the Evrysdi tablet was based on the results of a bioequivalence study, which demonstrated that the 5 mg tablet, whether swallowed whole or dispersed in non-chlorinated drinking water (eg, filtered water), and original oral solution provide comparable exposure to risdiplam.
- The Evrysdi oral solution will remain available for those on other doses of Evrysdi and for those who may prefer the oral solution.
- In patients 2 years of age and older weighing 20 kg or more, the recommended dose for Evrysdi tablet is **5 mg once daily**.
  - Refer to the Evrysdi drug label for dosing with the oral solution.
- Roche plans to launch Evrysdi tablet in the coming weeks.



At Optum, we help create a healthier world, one insight, one connection, one person at a time. All Optum trademarks and logos are owned by Optum, Inc., in the U.S. and other jurisdictions. All other trademarks are the property of their respective owners. This document contains information that is considered proprietary to Optum Rx and should not be reproduced without the express written consent of Optum Rx. RxNews<sup>®</sup> is published by the Optum Rx Clinical Services Department.